VolitionRX Ltd (VNRX) FinancialsVNRXVolitionRX Ltd

Evaluating the bottom line, VolitionRX Ltd maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1042.50%, while the net margin is -1834.98%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively VNRX converts its operational activities into shareholder value.

In the context of the broader market, VNRX competes directly with industry leaders such as CDIO and NVNO. With a market capitalization of $5.82M, it holds a leading position in the sector. When comparing efficiency, VNRX's gross margin of 100.00% stands against CDIO's 100.00% and NVNO's N/A. Such benchmarking helps identify whether VolitionRX Ltd is trading at a premium or discount relative to its financial performance.

VolitionRX has shown significant revenue growth, reporting approximately $1 million in Q1 2026, a 400% increase from the previous year, but continues to face substantial net income losses, with a net income of -$7,326,047 in Q2 2026.